Cephacare Flavour Study Proves Winning Formula

Animalcare’s new Cephacare flavour antibiotic has received a response of ‘good’ or ‘very good’ in 80% of cases in a recent field study of superficial pyoderma in dogs. When asked to rate the effectiveness of the cephalexin-based antibiotic, more than half of the cases were awarded the highest response level of ‘very good’. Animalcare representative, Sarah Abbott presents a manual to Pauline Sell from Bishops Stortford. Animalcare asked vets from across the country to participate in the study in order to confirm the company’s own opinion. Each vet recorded five cases of superficial pyoderma in dogs and scored the effectiveness of treating the condition with Cephacare flavour. The antibiotic proved effective across 19 different breeds, with animal weights ranging from 7kg to 70kg. Varying degrees of condition severity from mild through to severe were recorded with the average treatment length being 14-17 days. A number of ‘severe’ cases were treated with positive results. Severe was defined as long standing or recurrent areas of papules, crusting papules, epidermal collarettes and intact pustules. Tony Liepman, Animalcare Market Manager, said it was important to get feedback directly from their customers. “A study like this confirms the product’s effectiveness and, importantly, the acceptance of Cephacare flavour in real-world cases.” The first vets to complete their assessment forms received a free copy of the BSAVA Manual of Small Animal Dermatology worth £85. Cephacare flavour has a yeast-extract beef flavour that helps to improve compliance. Tablets are available in 50mg, 250mg and 500mg strengths and are scored to enable pet owners to accurately dose cats and dogs across a wide range of body weights. The 50mg strength is licensed for both cats and dogs and the 250 and 500mg for dogs, Cephacare flavour is highly effective in the treatment of skin infection particularly pyoderma as well as in respiratory, urinary tract and gastrointestinal infections. Cephalexin’s proven efficacy, broad spectrum of activity and excellent safety profile makes it the standard in treating skin infections in cats and dogs.

More from

• IVC Evidensia assembles expert team to run new £10m referral hospital
• Home delivery service can increase pet health plan sign-ups by 25%
• Research reveals vital clues to help fight anthelmintic resistance
• Lifetime Achievement Award recognises Harrogate vet’s dedication to improving the health and welfare of rabbits
• Bake sale at Leicestershire vet practice for good cause